Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Yanovsky, Yevgenij ^a   Schubring, Stephan R ^a   Yao, Quiaoling ^b   Zhao, Yan ^b   Li, Sha ^a,b   May, Andrea ^a   Haas, Helmut L ^a   Lin, Jian Sheng ^b   Sergeeva, Olga A ^a  

^a Department of Orthopedic Surgery   (Germany)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR BETA1; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; AMPA RECEPTOR; HISTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROSTEROID; PREGNENOLONE SULFATE; URSODEOXYCHOLIC ACID;

ALERTNESS; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL ISOLATION; CELL STRAIN HEK293; CELL SYNCHRONIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EVENING DOSAGE; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE MUTATION; HYPOTHALAMUS; MALE; MINIATURE ENDPLATE POTENTIAL; MORNING DOSAGE; MOUSE; NERVE CELL CULTURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; SLEEP WAKING CYCLE; STRUCTURE ACTIVITY RELATION; WAKEFULNESS; WILD TYPE;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ANIMALS; GABA-A RECEPTOR ANTAGONISTS; HISTAMINE; HYPOTHALAMIC AREA, LATERAL; INHIBITORY POSTSYNAPTIC POTENTIALS; KINETICS; MICE; MUTANT PROTEINS; MUTATION; NEURONS; PICROTOXIN; RECEPTORS, GABA-A; RECOMBINANT PROTEINS; STEROIDS; TIME FACTORS; URSODEOXYCHOLIC ACID; WAKEFULNESS;

MUS;

EID: 84864688815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042512     Document Type: Article

References (44)

1. Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, et al. ((2007)) Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol 2:155-177.
2. Woo SJ, Kim JH, Yu HG, ((2010)) Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model. J Ocul Pharmacol Ther 26:223-229.
3. Boatright JH, Moring AG, McElroy C, Phillips MJ, Do VT, et al. ((2006)) Tool from ancient pharmacopoeia prevents vision loss. Mol Vis 12:1706-14.: 1706-1714.
4. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, et al. ((2002)) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A 99:10671-10676.
5. Sola S, Amaral JD, Borralho PM, Ramalho RM, Castro RE, et al. ((2006)) Rodrigues,C.M., Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis. Mol Endocrinol 20:2292-2303.
6. Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM, ((2008)) Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med 14:54-62.
7. Roda E, Azzaroli F, Nigro G, Piazza F, Jaboli F, et al. ((2002)) Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis 34:523-527.
8. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A, ((2004)) Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40:693-698.
9. Bergasa NV, ((2008)) Update on the treatment of the pruritus of cholestasis. Clin Liver Dis 12:219-34.
10. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, et al. ((2006)) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489.
11. Keitel V, Kubitz R, Haussinger D, ((2008)) Endocrine and paracrine role of bile acids. World J Gastroenterol 14:5620-5629.
12. Schubring SR, Fleischer W, Lin JS, Haas HL, Sergeeva OA, ((2012)) The bile steroid chenodeoxycholate is a potent antagonist at NMDA and GABA(A) receptors. Neurosci Lett 506:322-326.
13. Anaclet C, Parmentier R, Ouk K, Guidon G, Buda C, et al. ((2009)) Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 29:14423-14438.
14. Haas HL, Sergeeva OA, Selbach O, ((2008)) Histamine in the nervous system. Physiol Rev 88:1183-1241.
15. Franks NP, ((2008)) General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 9:370-386.
16. Yanovsky Y, Li S, Klyuch BP, Yao Q, Blandina P, et al. ((2011)) L-Dopa activates histaminergic neurons. J Physiol 589:1349-1366.
17. Lin JS, Sakai K, Vanni-Mercier G, Jouvet M, ((1989)) A critical role of the posterior hypothalamus in the mechanisms of wakefulness determined by microinjection of muscimol in freely moving cats. Brain Res 479:225-240.
18. Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, et al. ((2002)) The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 5:979-984.
19. Cauli O, Mansouri MT, Agusti A, Felipo V, ((2009)) Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex. Gastroenterology 136:1359-1402.
20. Sola S, Amaral JD, Castro RE, Ramalho RM, Borralho PM, et al. ((2005)) Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 42:925-934.
21. Chepkova AN, Sergeeva OA, Haas HL, ((2008)) Carbenoxolone impairs LTP and blocks NMDA receptors in murine hippocampus. Neuropharmacology 55:139-147.
22. Yanovsky Y, Schubring S, Fleischer W, Gisselmann G, Zhu XR, et al. ((2012)) GABA(A) receptors involved in sleep and anaesthesia: beta1- versus beta3-containing assemblies. Pflugers Arch 463:187-99.
23. Sergeeva OA, Kletke O, Kragler A, Poppek A, Fleischer W, et al. ((2010)) Fragrant Dioxane Derivatives Identify beta1-Subunit-containing GABAA Receptors. J Biol Chem 285:23985-23993.
24. Olsen RW, Sieghart W, ((2008)) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 60:243-260.
25. Sergeeva OA, Andreeva N, Garret M, Scherer A, Haas HL, ((2005)) Pharmacological properties of GABAA receptors in rat hypothalamic neurons expressing the epsilon-subunit. J Neurosci 25:88-95.
26. Saras A, Gisselmann G, Vogt-Eisele AK, Erlkamp KS, Kletke O, et al. ((2008)) Histamine action on vertebrate GABAA receptors: direct channel gating and potentiation of GABA responses. J Biol Chem 283:10470-10475.
27. Shen W, Mennerick S, Covey DF, Zorumski CF, ((2000)) Pregnenolone sulfate modulates inhibitory synaptic transmission by enhancing GABA(A) receptor desensitization. J Neurosci 20:3571-3579.
28. Akk G, Bracamontes J, Steinbach JH, ((2001)) Pregnenolone sulfate block of GABA(A) receptors: mechanism and involvement of a residue in the M2 region of the alpha subunit. J Physiol 532:673-684.
29. Hosie AM, Wilkins ME, da Silva HM, Smart TG, ((2006)) Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 444:486-489.
30. Perret P, Sarda X, Wolff M, Wu TT, Bushey D, et al. ((1999)) Interaction of non-competitive blockers within the gamma-aminobutyric acid type A chloride channel using chemically reactive probes as chemical sensors for cysteine mutants. J Biol Chem 274:25350-25354.
31. Oveson BC, Iwase T, Hackett SF, Lee SY, Usui S, et al. ((2011)) Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration. J Neurochem 116:144-153.
32. Nobilis M, Pour M, Kunes J, Kopecky J, Kvetina J, et al. ((2001)) High-performance liquid chromatographic determination of ursodeoxycholic acid after solid phase extraction of blood serum and detection-oriented derivatization. J Pharm Biomed Anal 24:937-946.
33. Dalpiaz A, Paganetto G, Pavan B, Fogagnolo M, Medici A, et al. ((2012)) Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system. Mol Pharm 9:957-968.
34. Lin JS, Anaclet C, Sergeeva OA, Haas HL, ((2011)) The waking brain: an update. Cell Mol Life Sci 68:2499-512.
35. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, et al. ((2003)) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278:9435-9440.
36. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, et al. ((2009)) Bile acids as regulatory molecules. J Lipid Res 50:1509-1520.
37. Hatton GI, Yang QZ, ((2001)) Ionotropic histamine receptors and H2 receptors modulate supraoptic oxytocin neuronal excitability and dye coupling. J Neurosci 21:2974-2982.
38. Lu JW, Fenik VB, Branconi JL, Mann GL, Rukhadze I, et al. ((2007)) Disinhibition of perifornical hypothalamic neurones activates noradrenergic neurones and blocks pontine carbachol-induced REM sleep-like episodes in rats. J Physiol 582:553-567.
39. Jimenez-Anguiano A, Diaz-Medina V, Farfan-Labonne BE, Giono-Chiang G, Kersenobich D, et al. ((2009)) Modification of sleep architecture in an animal model of experimental cirrhosis. World J Gastroenterol 15:5176-5180.
40. Parmentier R, Kolbaev S, Klyuch BP, Vandael D, Lin JS, et al. ((2009)) Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci 29:4471-4483.
41. Vorobjev VS, Sharonova IN, Haas HL, ((1996)) A simple perfusion system for patch-clamp studies. J Neurosci Methods 68:303-307.
42. Woodhull AM, ((1973)) Ionic blockage of sodium channels in nerve. J Gen Physiol 61:687-708.
43. Sergeeva OA, Klyuch BP, Fleischer W, Eriksson KS, Korotkova TM, et al. ((2006)) P2Y receptor-mediated excitation in the posterior hypothalamus. Eur J Neurosci 24:1413-1426.
44. Akk G, Li P, Bracamontes J, Reichert DE, Covey DF, et al. ((2008)) Mutations of the GABA-A receptor alpha1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids. Mol Pharmacol 74:614-627.